New Tumor Biomarker, Cardiovascular and Alzheimer-related Peptides

CGRP precursor human
CGRP rat
sequence comparison cgrp2
sequence comparison cgrp3

sequence comparison cgrp1
In cystic fibrosis (CF), a lack of functional CF transmembrane conductance regulator (CFTR) chloride channels causes defective secretion by submucosal glands (SMGs), leading to persistent bacterial infection that damages airways and necessitates tissue repair. SMGs are also important niches for slow-cycling progenitor cells (SCPCs) in the proximal airways, which may be involved in disease-related airway repair. Here, we report that calcitonin gene–related peptide (CGRP) activates CFTR-dependent SMG secretions and that this signaling pathway is hyperactivated in CF human, pig, ferret, and mouse SMGs. Since CGRP-expressing neuroendocrine cells reside in bronchiolar SCPC niches, we hypothesized that the glandular SCPC niche may be dysfunctional in CF. Consistent with this hypothesis, CFTR-deficient mice failed to maintain glandular SCPCs following airway injury. In wild-type mice, CGRP levels increased following airway injury and functioned as an injury-induced mitogen that stimulated SMG progenitor cell proliferation in vivo and altered the proliferative potential of airway progenitors in vitro. Components of the receptor for CGRP (RAMP1 and CLR) were expressed in a very small subset of SCPCs, suggesting that CGRP indirectly stimulates SCPC proliferation in a non-cell-autonomous manner. These findings demonstrate that CGRP-dependent pathways for CFTR activation are abnormally upregulated in CF SMGs and that this sustained mitogenic signal alters properties of the SMG progenitor cell niche in CF airways. This discovery may have important implications for injury/repair mechanisms in the CF airway.

Xie W, Fisher JT, Lynch TJ, et al. CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice. J Clin Invest. 2015;125(5):2179.

BACKGROUND: We evaluated the variation of calcitonin gene related peptide (CGRP) expression in patients with mixed invasive with extensive in situ ductal carcinomas (IDC + DCIS) and pure IDC, in relation to mammographic breast density (%BD), proliferation-seeking radiotracer (99m)Tc(V) dimercaptosuccinic acid (DMSA) uptake (scintimammographic-SMM), proliferation index Ki-67, and estrogen receptor (ER) status. We also assessed CGRP expression with histological grade.
METHODS: We studied retrospectively 24 women with suspicious findings on mammography who were evaluated preoperatively with (99m)Tc(V)DMSA scintimammography. Histology revealed 12 IDC (grade II in 8, grade III in 4 patients; mean size ± SD, 2.6 ± 1.3 cm; mean age ± SD, 66.5 ± 13.1 years) and 12 IDC + DCIS (grade II in 6, grade III in 6 patients; DCIS component mean size ± SD, 5.3 ± 1.8 cm; IDC component mean size ± SD, 2.5 ± 1.1 cm; mean age ± SD, 58.5 ± 15.1 years). Immunohistochemistry for CGRP, Ki-67, and ER status was performed in all 24 surgical specimens. BD and SMM were calculated by computer-assisted methods and were statistically correlated with CGRP expression. BD, SMM, Ki-67, and ER were statistically compared between IDC and IDC + DCIS, whereas CGRP, Ki-67, and ER were compared between patients with BD >25 and <25%. CGRP was also compared (t test) between grade II and grade III in both groups.
RESULTS: Overall positive correlation was found between BD and CGRP (r = 0.577, P < 0.001). Positive correlation was established between SMM and CGRP only in IDC + DCIS (r (SMM(IDC+DCIS)-CGRP) = 0.634, P < 0.05). CGRP and Ki-67 were significantly higher in patients with BD >25% compared with <25% BD patients (P = 0.00008 and P = 0.014, respectively). BD and SMM were significantly higher in CGRP(+) than in CGRP(-) patients as well as in IDC + DCIS compared with IDC. Ki-67 was significantly higher, whereas ER was significantly lower, in IDC + DCIS than in IDC. In all patients, CGRP was significantly higher in grade II as compared with grade III (P = 0.005). In the mixed group (IDC + DCIS), grade II cancers had also significantly higher CGRP values as compared with grade III ones (P = 0.004). In pure IDC, no statistical difference was found between grade II and III (P = 0.4).
CONCLUSIONS: ΒD, SMM, CGRP, and Ki-67 were significantly increased, whereas ER was significantly decreased, in IDC + DCIS as compared with IDC, indicating that IDC + DCIS is an entity that is more aggressive, ER independent, and possibly associated with a pathway linked to stromal involvement and CGRP activity.

Papantoniou V, Sotiropoulou E, Valsamaki P, et al. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. Breast Cancer. 2011;18(4):286-91.

The calcitonin/CGRP multigene complex encodes a family of peptides: calcitonin, its C-terminal flanking peptide, katacalcin, and a third novel peptide, calcitonin gene-related peptide (CGRP). The 32-amino acid peptide calcitonin inhibits the osteoclast, thereby conserving skeletal mass during periods of potential calcium lack, such as pregnancy, growth, and lactation. This hormonal role is emphasized by observations that lower circulating calcitonin levels are associated with bone loss and that calcitonin replacement prevents further bone loss. Structurally, CGRP resembles calcitonin and has been implicated in neuromodulation and in the physiological regulation of blood flow. Here we review the molecular genetics, structure, and function of the calcitonin-gene peptides as analyzed in the laboratory and focus on more recent clinical studies relating to disorders and therapeutics.

Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci. 1990;28(2):109-74.

Updates coming soon.

Related Products

Catalog# Product Standard Size Price
EK-015-02 CGRP (Human) - EIA Kit 96 wells $458
EK-014-09 Calcitonin (Salmon) - EIA Kit 96 wells $458
EK-015-09 CGRP (Rat, Mouse) - EIA Kit 96 wells $458
015-02 CGRP (Human) 200 µg $71
015-09 CGRP (Rat, Mouse) 200 µg $71
014-06 Calcitonin (Rat) 500 µg $66
H-015-09 CGRP (Rat, Mouse) - Antibody 50 µl $179
EK-014-06 Calcitonin (Rat) - EIA Kit 96 wells $458
015-06 CGRP (8-37) (Human) 200 µg $56
FEK-015-02 CGRP (Human) - Fluorescent EIA Kit 96 wells $500
014-22 Calcitonin (Mouse) 100 µg $122
EK-014-03 Calcitonin (Human, Monkey) - EIA Kit 96 wells $458
RK-014-06 Calcitonin (Rat) - RIA Kit 125 tubes $588
014-03 Calcitonin (Human, Monkey) 500 µg $92
015-28 CGRP (1-17) (Human) 100 µg $102
RK-015-09 CGRP (Rat, Mouse) - RIA Kit 125 tubes $588
EK-015-02CE CGRP (Human) - EIA Kit, CE Mark Certified 96 wells $478
FEK-015-02CE CGRP (Human) - Fluorescent EIA Kit, CE Mark Certified 96 wells $520
EK-014-03CE Calcitonin (Human, Monkey) - EIA Kit, CE Mark Certified 96 wells $478
010-66 C7 / Calcitonin Receptor Antagonist 100 µg $184
015-29 CGRP (1-25) (Human) 100 µg $122
015-31 CGRP (1-54) (Human) 100 µg $357
015-03 CGRP (17-37) (Human) 200 µg $77
FG-015-03A CGRP (17-37) (Human) - FAM Labeled 1 nmol $204
FR-015-03 CGRP (17-37) (Human) - Rhodamine Labeled 1 nmol $204
015-13 CGRP (29-37) (Rat, Mouse) 500 µg $97
015-14 CGRP (30-37) (Rat, Mouse) 500 µg $87
015-15 CGRP (31-37) (Rat, Mouse) 500 µg $77
015-16 CGRP (32-37) (Rat, Mouse) 500 µg $56
015-17 CGRP (33-37) (Rat, Mouse) 500 µg $56

1 2 3 4 Next  Last